Cresco Labs Past Earnings Performance

Past criteria checks 0/6

Cresco Labs's earnings have been declining at an average annual rate of -16.7%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 21.8% per year.

Key information

-16.7%

Earnings growth rate

-4.9%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth rate21.8%
Return on equity-15.3%
Net Margin-9.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Oct 24
Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Aug 11
Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Jul 17
Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Jun 19
Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 19
Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Mar 16
Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Mar 03
Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Jan 26
Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Jan 04
Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Is Cresco Labs (CSE:CL) Using Too Much Debt?

Sep 22
Is Cresco Labs (CSE:CL) Using Too Much Debt?

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Aug 11
Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

Jan 25
Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?

Dec 13
Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?

We Think Cresco Labs (CSE:CL) Is Taking Some Risk With Its Debt

Aug 22
We Think Cresco Labs (CSE:CL) Is Taking Some Risk With Its Debt

Estimating The Intrinsic Value Of Cresco Labs Inc. (CSE:CL)

May 23
Estimating The Intrinsic Value Of Cresco Labs Inc. (CSE:CL)

Revenue & Expenses Breakdown

How Cresco Labs makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:CL Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24726-672230
30 Jun 24735-1722270
31 Mar 24747-1552410
31 Dec 23756-1762600
30 Sep 23767-3392840
30 Jun 23786-2342950
31 Mar 23806-2113070
31 Dec 22825-2123100
30 Sep 22842-652950
30 Jun 22848-3262950
31 Mar 22841-3182920
31 Dec 21806-3202760
30 Sep 21750-3602760
30 Jun 21687-732460
31 Mar 21573-1052150
31 Dec 20463-1021990
30 Sep 20345-761630
30 Jun 20231-981450
31 Mar 20168-641190
31 Dec 19124-43920
30 Sep 19101-20770
30 Jun 1978-14630
31 Mar 1957-12460
31 Dec 1841-2310
30 Sep 18280190
30 Jun 1819190
31 Mar 1813170
31 Dec 1710-350
31 Dec 163-840

Quality Earnings: CL is currently unprofitable.

Growing Profit Margin: CL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CL is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.

Accelerating Growth: Unable to compare CL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-51.1%).


Return on Equity

High ROE: CL has a negative Return on Equity (-15.34%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies